Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

Affiliations

• ¹ Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
• ² Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; Medical School Hamburg, University of Applied Sciences and Medical University, Hamburg, Germany.
• ³ Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Urology, Austin Health, Heidelberg, Australia.
• ⁴ Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Urology, Royal Melbourne Hospital, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
• ⁵ Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. Electronic address: declan.murphy@petermac.org.